XML 30 R7.htm IDEA: XBRL DOCUMENT v3.19.3
Condensed Consolidated Statements of Cash Flows - USD ($)
 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Cash flows from operating activities:    
Net income $ 124,492,000 $ 117,962,000
Adjustments to reconcile net income to net cash provided by operating activities:    
Tax benefit from stock-based compensation 16,187,000 17,169,000
Depreciation and amortization 897,000 24,000
Loss on disposal of fixed assets 4,050,000 0
Impairment of Leasehold 1,883,000 0
Impairment of intangible 385,000 1,960,000
Deferred taxes (29,000) (35,000)
Accrued interest on note receivable - related party 17,636,000 15,340,000
Deferred rent benefit 0 (326,000)
Marketable Securities, Realized Gain (Loss) (5,000) (182,000)
Changes, net of acquisitions, in:    
Accounts receivable (8,005,000) (9,788,000)
Factor accounts receivable (56,327,000) (81,353,000)
Notes receivable - related party (1,453,000) (37,167,000)
Repayment of Notes Receivable from Related Parties 307,000 307,000
Inventories 3,688,000 5,234,000
Prepaid expenses, prepaid taxes, deposits and other (16,015,000) 18,816,000
Increase (Decrease) in Employee Related Liabilities (276,000) (1,898,000)
Increase (Decrease) in Other Accrued Liabilities (2,140,000) 39,000
Net cash provided by operating activities 83,158,000 46,466,000
Net benefit in connection with reversal of contingent liability partially offset by acceleration of amortization related to Kate Spade license termination (1,868,000) 0
Provision for Doubtful Accounts (259,000) 0
Cash flows from investing activities:    
Capital expenditures (9,211,000) (8,164,000)
Purchases of marketable securities (37,426,000) (42,531,000)
Repayment of notes receivable 77,757,000 76,373,000
Acquisitions, net of cash acquired (36,753,000) 0
Net cash (used in)/provided by investing activities (5,633,000) 25,678,000
Cash flows from financing activities:    
Proceeds from exercise of stock options (76,505,000) (50,880,000)
Payments of Dividends (35,805,000) (35,147,000)
Tax benefit from the exercise of options 2,606,000 12,801,000
business combinations contingent liability payment 0 7,000,000
Net cash (used in) financing activities (109,534,000) (80,226,000)
Effect of Exchange Rate on Cash and Cash Equivalents (530,000) (595,000)
Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests 1,283,000 0
Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders (1,113,000) 0
Net (decrease) in cash and cash equivalents (32,539,000) (8,677,000)
Cash and cash equivalents – beginning of period 200,031,000 181,214,000
Cash and cash equivalents – end of period $ 167,492,000 $ 172,537,000